Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

Summary

This phase II trial studies aim to evaluate the initial efficacy of leflunomide tablets in second-line treatment of advanced MEN-1 neuroendocrine tumors, and to provide evidence for phase III clinical trials.

Timeline

Start

2020-07-01

Primary completion

2024-12-30

Completion

2024-12-30

Publications

• Results Ma Y, Zhu Q, Wang X, Liu M, Chen Q, Jiang L, Chi Y, Zeng YX, Zhao H, Jiao Y. Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cells. Cell Res. 2022 Jun;32(6):596-599. doi: 10.1038/s41422-022-00613-1. Epub 2022 Feb 15. No abstract available.

Drugs

Indications